Trophoblast Neoplasia




Abstract


Gestational trophoblastic disease (GTD) is a spectrum of abnormal gestations and neoplasms arising from villous or extravillous trophoblast. Molar pregnancy arises secondary to abnormal fertilization, with excess paternal DNA, resulting in hydropic villi with concentric trophoblast hyperplasia. In a complete mole, no fetal tissue is present and cyto- and syncytiotrophoblast proliferation is pronounced; partial mole, on the other hand, includes fetal tissue, and shows a biphasic population of villi, one of which shows cavitation, with concentric syncytiotrophoblast hyperplasia. The technique of choice for resolving difficult cases of suspected complete mole is immunostaining for p57 KIP-2 . The lack of expression of this marker in villous cytotrophoblast and stromal cells will accurately distinguish a complete mole from partial and nonmolar gestations 99% of the time. Any suspected mole, complete or partial, should be managed with a follow-up monitoring for beta–human chorionic gonadotropin (β-hCG). Persistent GTD, including invasive or metastatic mole and choriocarcinoma, can follow a hydatidiform mole, most commonly a complete mole. Choriocarcinoma, a malignant tumor of villous trophoblast, is defined by presence of sheets of biphasic trophoblast (cytotrophoblast and syncytiotrophoblast), often accompanied by extensive necrosis and hemorrhage. Placental site trophoblastic tumors/epithelioid trophoblastic tumors (PSTTs/ETTs) are malignant tumors originating from extravillous trophoblast. They are distinguished from their benign counterparts, exaggerated implantation site/placental site nodule, by a high proliferation index. Although persistent molar gestations and choriocarcinomas are highly responsive to chemotherapy, PSTT/ETT requires surgery followed by adjuvant chemotherapy for higher stage disease.




Keywords

complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), choriocarcinoma, placental site trophoblastic tumor (PSTT), epithelioid trophoblastic tumor (ETT)

 





Introduction


Gestational trophoblastic disease (GTD) is defined as a spectrum of abnormal gestations and neoplasms arising from villous or extravillous trophoblast that are associated with pregnancy. As discussed in this chapter, GTD may take several forms, each with its own risk of mortality and responsiveness to chemotherapy. The gestational nature of these disorders justifies their discussion in the context of pregnancy evaluation as (1) most cases are directly related to a pregnancy, (2) the evaluation of each pregnancy requires the exclusion of trophoblastic neoplasia, and (3) a high percentage of hydatidiform moles are discovered in the first trimester. The most common types of trophoblastic lesions occur primarily in the first trimester of pregnancy and consist (in descending order of frequency) of partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), placental site trophoblastic tumor (PSTT), and choriocarcinoma. The best studied are the CHMs, which are genetically abnormal gestations carrying a significant risk of subsequently developing gestational trophoblastic neoplasia, including choriocarcinoma. A pathologic diagnosis of a hydatidiform mole should prompt the clinician to serially monitor the patient’s serum beta–human chorionic gonadotropin (β-hCG) for regression. The clinical features of these tumors, histopathology, and management are detailed in Tables 30.1 through 30.5 .



Table 30.1

Clinico-Radiologic and Gross Pathologic Presentation of Trophoblastic Neoplasia




















































Disorder Clinico-Radiologic Features Beta–Human Chorionic Gonadotropin Endometrial Curettings/Hysterectomy (Gross) Exclude
PHM


  • 11 to 25 weeks’ gestation



  • ± fetal cardiac activity



  • Vaginal bleeding



  • Missed/incomplete pregnancy loss

Variable


  • Moderate amount of tissue



  • Hydropic and normal villi



  • Sac/membranes



  • ± fetal parts (esp. syndactyly)




  • SAB



  • CHM



  • Aneuploid gestation (e.g., trisomy 13)

CHM


  • “Snowstorm” U/S



  • Vaginal bleeding



  • Toxemia



  • Hyperemesis



  • Thyrotoxicosis a

High (>100K mIU/mL)


  • Voluminous grapelike, transparent vesicles



  • Ectopic pregnancy



  • Mild diffuse swelling under dissecting microscope (early CHM)




  • SAB



  • PHM

Persistent GTD/invasive mole


  • Vaginal bleeding



  • Prior CHM or PHM

Plateau (<10% drop in 14 days) or rising (>10% increase × 3 weeks)


  • Minimal residual villous tissue



  • Subtle, sometimes hemorrhagic myometrial nodule




  • Choriocarcinoma



  • Unsuspected degenerating IUP

Choriocarcinoma


  • Irregular/severe bleeding



  • Recent CHM or normal pregnancy



  • Pulmonary, neurologic, or gastrointestinal symptoms




  • Rising, 2 weeks after delivery



  • After CHM: plateau (<10% drop in 14 days) or rising (>10% incr. × 3 weeks)

Hemorrhagic tumor nodules in endomyometrium


  • Persistent mole



  • PSTT



  • Unsuspected degenerating IUP

PSTT


  • Irregular vaginal bleeding



  • Pregnancy months to years earlier

Persistent, low (50 mU/mL) Discrete or infiltrative, polypoid or endophytic, tan, fleshy mass in endomyometrium


  • Exaggerated implantation site



  • Placental site nodule



  • Ectopic pregnancy



  • Unsuspected IUP

ETT


  • Irregular vaginal bleeding



  • Pregnancy months to years earlier

Persistent low
(<150 mU/mL)
Expansile mass, may be centered in cervix or lower uterine segment


  • Squamous cell carcinoma



  • Placental site nodule



  • Ectopic pregnancy



  • PSTT

Spontaneous pregnancy loss/SAB Vaginal bleeding, first/second trimester Declining Minimal villous edema (not typically grossly evident; by dissecting microscope or histology usually)


  • CHM



  • PHM



  • Ectopic pregnancy


β-hCG, Beta–human chorionic gonadotropin; CHM, complete hydatidiform mole; ETT, epithelioid trophoblastic tumor; GTD, gestational trophoblastic disease; IUP, intrauterine pregnancy; PHM, partial hydatidiform mole; PSTT, placental site trophoblastic tumor; SAB, spontaneous abortion; U/S, ultrasound.

a With first trimester ultrasound screening and quantitative β-hCG, complete hydatidiform moles are most often diagnosed before clinical manifestations are evident.



Table 30.2

Trophoblastic Neoplasia, Histologic Classification, Diagnosis, and Exclusions


























































Disorder Villi Trophoblast Exclusions Ancillary Studies
PHM


  • Both large and normal



  • Scalloped contours



  • Cisterns (variable)



  • Nucleated RBCs




  • Focal mild syn-cytotrophoblast “hyperplasia” or lack of attenuation in larger villi



  • Trophoblast inclusions



  • Infrequent conspicuous implantation site atypia




  • Hydropic abortus



  • Beckwith-Wiedemann syndrome



  • Trisomic (aneuploid) gestations with mild villous irregularity



  • Nonmolar (dygynic) triploidy




  • Flow: Triploid



  • Karyotype: 70% 69, XXY; 27% 69, XXX; 3% 69, XYY



  • Immunostain: p57 KIP2 (present)



  • Molecular markers: 3n diandry

CHM


  • Diffusely and variably enlarged



  • Focal prominent cisterns

Diffuse triphasic trophoblast hyperplasia and atypia


  • Hydropic abortus



  • Very early genetically normal gestation



  • ChorioCa



  • Collapsed gestation sac




  • Flow: Diploid



  • Immunostain: p57 KIP2 (absent in cytotrophoblast and villous stromal cells)



  • Karyotype: 46, XX (most); rarely 46, XY

Early CHM


  • Scattered, slightly enlarged



  • Subtle cavitation



  • Hypercellular stroma in blue myxoid matrix



  • Stromal karyorrhexis



  • Degenerating blood vessels, generally without nucleated RBCs




  • Focal to diffuse trophoblast hyperplasia and atypia



  • Atypical implantation site




  • Hydropic abortus



  • PHM




  • Flow: Diploid



  • Immunostain: p57 KIP2 (absent in cytotrophoblast and villous stromal cells)



  • Karyotype: 46, XX (most); rarely 46, XY

ChorioCa None present Dimorphic/biphasic trophoblast atypia


  • Persistent CHM



  • PSTT



  • Hemorrhage and necrosis

Immunostain: Strongly β-hCG and inhibin positive
PSTT None present


  • Sheets of atypical mature implantation trophoblast



  • Dissection between muscle fibers



  • Mitoses




  • Exaggerated implantation site



  • ChorioCa



  • Persistent CHM




  • Immunostain: hPL +; MelCAM +; β-hCG ±



  • MIB-1 fraction of MelCAM+ cells: >1% (often >10%)

ETT None present


  • Nests or cords of cells, some with central necrosis or calcification



  • Round cells with moderate eosinophilic or clear vacuolated cells



  • Increased mitotic activity




  • Squamous cell carcinoma



  • Placental site nodule



  • Ectopic pregnancy



  • PSTT




  • Diffusely p63 +



  • ≥10% MIB-1 fraction



  • hPL −; β-hCG −; MelCAM (CD146) −

Hydropic abortus Gradual differences in villous size with edema


  • Minimal or polar/eccentric trophoblast proliferation only



  • No implantation site atypia




  • Early CHM



  • PHM



  • Twin (CHM and normal)




  • Flow: Diploid



  • Immunostain: p57 KIP2 (present)

Aneuploid gestation (e.g., trisomy 13)


  • Dysmorphic villi with complex shapes, but without distinctly biphasic size distribution



  • No or extremely rare villous cavitation




  • Minimal or polar trophoblast proliferation only



  • No trophoblast atypia




  • Early gestation



  • PHM



  • Early CHM




  • Flow: Near diploid



  • Karyotype: Trisomy


β-hCG, Beta–human chorionic gonadotropin; ChorioCa, choriocarcinoma; CHM, complete hydatidiform mole; ETT, epithelioid trophoblastic tumor; Flow, flow cytometry; hPL, human placental lactogen; PHM, partial hydatidiform mole; PSTT, placental site trophoblastic tumor; RBC, red blood cell.


Table 30.3

Management and Outcome of Trophoblastic Neoplasia


































Disorder Therapy Risk of Progression Comments/Caveats
PHM

  • 1.

    Suction curettage


  • 2.

    Follow β-hCG every week until <5 mIU/mL × 3 weeks, then every month × 6 months, then every year × 1 to 3 years


  • 3.

    Contraception × 1 year




  • Persistent GTD = 4% to 15% (often as retained products of conception with no or minimal proliferation)



  • ChorioCa = essentially 0%

Confusion with a twin complete and normal gestation (rare)
CHM


  • Low-risk; same as PHM



  • High-risk; chemoprophylaxis




  • Persistent GTD = 10% to 30%



  • Invasive mole = 15%



  • ChorioCa: 2% to 3%

If persistently elevated β-hCG: 75% have persistent GTD; 25% risk of ChorioCa
Persistent invasive mole

  • 1.

    Evaluate for metastatic disease


  • 2.

    Single-agent chemo until β-hCG <5 mIU/mL


  • 3.

    Contraception for 1 year


  • 4.

    Hysterectomy for local control (optional) or bleeding complications

“Persistent GTD” is a clinical diagnosis applied to persistently elevated serum β-hCG following molar pregnancy and often treated empirically without pathologic sampling to distinguish persistent/invasive mole versus ChorioCa
Choriocarcinoma

  • 1.

    Evaluate for metastatic disease


  • 2.

    Single-agent chemo if low risk


  • 3.

    Multiagent chemo if high risk


  • 4.

    Hysterectomy for local control (optional) (see Tables 30.8 and 30.9 )




  • Based on FIGO staging and WHO score



  • Remission:



  • No metastases = 80%



  • Metastases = 67%



  • Overall disease-free survival with single-agent chemo = 87%

PSTT and ETT

  • 1.

    Hysterectomy (therapy of choice)


  • 2.

    Evaluate for metastatic disease


  • 3.

    Multiagent chemo




  • Nonmetastatic disease: Cured by surgery



  • Metastases = >30% at diagnosis



  • Recurrence = 30%



  • Mortality: 21% to 36%

Poor prognosis: >5 mitoses/10 HPFs (recurrence), pulmonary metastases, antecedent pregnancy >4 years prior

β-hCG, Beta–human chorionic gonadotropin; chemo, chemotherapy; CHM, complete hydatidiform mole; ChorioCa, choriocarcinoma; ETT, epithelioid trophoblastic tumor; FIGO, International Federation of Gynecology and Obstetrics; GTD, gestational trophoblast disease; HPF, high-power field; PHM, partial hydatidiform mole; PSTT, placental site trophoblastic tumor; WHO, World Health Organization.


Table 30.4

Sensitivity and Specificity of Parameters for Recognizing Complete Mole








































Feature Sensitivity Specificity
Absence of embryogenesis 100 79
Myxoid stroma 92 100
Implantation site atypia 77 96
Villous cavitation 92 85
Syncytiotrophoblastic “hyperplasia” and atypia 54 99
Cytotrophoblast hyperplasia and atypia 77 100
Syncytiotrophoblast “hyperplasia” and cavitation 92 95
Syncytiotrophoblast and cytotrophoblast hyperplasia and cavitation 85 100


Table 30.5

Sensitivity and Specificity of Parameters Distinguishing Partial and Complete Mole






























































Partial Mole Complete Mole
Sensitivity Specificity Histologic Features Sensitivity Specificity
79 77 Inclusion 18 51
100 22 Syncytiotrophoblast hyperplasia 80 17
100 35 Contour complexity 60 17
43 81 Enlargement 4 54
57 79 Cavitation 8 51
29 100 Inclusion + syncytiotrophoblast hyperplasia 0 86
79 83 Inclusion + complexity + enlargement 16 50
29 100 Cavitation + inclusion + enlargement + syncytiotrophoblast hyperplasia 0 93


The Patient at Risk


Risk factors for GTD include a range of epidemiologic and genetic parameters ( Table 30.6 ) and are most strongly associated with subtypes of GTD at greatest risk for either persisting or evolving into malignancy. The principal risk factors are advanced maternal age, Asian ethnicity, lower socioeconomic status (in selected populations), and one or more prior molar pregnancies. Two types of molar gestations have been recognized, and their incidence varies widely worldwide: CHM (prevalence approximately 1 per 1000 pregnancies) and PHM (prevalence approximately 1 per 100 pregnancies).



Table 30.6

Risk Factors for Trophoblastic Neoplasia












































































Factor Qualifier Relative Risk
Maternal age <20 years 1.5
>40 5.2
Prior SAB 1.9–3.3
Parity >1 0.4
Vitamin A Median consumption 0.6
Incidence
Race Indonesia 1 : 85
Japan 1 : 522
Sweden 1 : 1560
United States 1 : 1724
Socioeconomic status Philippines (wealthy) 1 : 2000
Philippines (poor) 1 : 200
Prior molar pregnancy 1 1 : 100
>1 1 : 6 to 1 : 4
Trend
Smoking >15 cigarettes/day Increasing
Infertility Increasing
Theca-lutein cyst >6 cm by ultrasound Increasing (GTD subsequently develops in up to 50%)

GTD, Gestational trophoblastic disease; SAB, spontaneous abortion.


Age


Molar gestations occur in women of all reproductive ages, but the highest incidence (per pregnancy) occurs in women over 40 years old, where the relative risk increases to more than 5. Women younger than 20 years old have a slightly increased risk as well (relative risk = 1.5).


Ethnicity


Another major risk factor for molar pregnancy is maternal Asian race. In Indonesia, the rate is more than 1 molar gestation in 100 pregnancies. The socioeconomic status of women within this population is also an important factor in some studies; poor individuals show a tenfold greater risk of GTD than wealthy individuals from the same Asian population.


Nulliparity and Prior Spontaneous Abortion


Nulliparity is associated with a slightly less than twofold increased risk of GTD. In one study, two or more spontaneous abortions conferred a 32-fold increase in risk of GTD.


Prior Hydatidiform Mole


Approximately 1% of pregnancies following a single hydatidiform mole will be a recurrent hydatidiform mole. If the patient has had two prior molar pregnancies, the risk is increased to 16% to 28%.


Molecular Pathogenesis


Complete and partial moles have different genetic, clinical, and pathologic features ( Fig. 30.1 ). A CHM develops when an empty (i.e., without female pronucleus) oocyte is fertilized by one or two spermatozoa, resulting in a diploid genome with two complete male-derived haploid chromosomal sets (diandry). In 90% of complete moles, a single 23,X spermatozoa duplicates its chromosome after fertilization, resulting in a 46,XX complete mole; in the remaining 10% of complete moles, two spermatozoa fertilize an empty egg, resulting in 46,XX or 46,XY molar karyotypes. PHMs result from two potential scenarios. In approximately three quarters of the partial mole cases, a normal egg is fertilized by two spermatozoa, resulting in diandric, monogynic triploidy (70% 69,XXY; 27% 69,XXX; 3% 69,XYY).




Fig. 30.1


Pathogenesis of trophoblastic neoplasia, including partial and complete mole. ChorioCa, Choriocarcinoma.


In the second scenario, nondisjunction in meiosis I or meiosis II of spermatogenesis results in an extra set of paternal chromosomes in one sperm (diandric), which fertilizes a haploid (monogynic) egg. It is important to realize that not all triploid gestations are partial moles; cases that have two haploid sets of maternal chromosomes resulting from nondisjunction in meiosis I or meiosis II of oogenesis and one haploid set of paternal chromosomes (monoandric and digynic) are abnormal but nonmolar (accounting for approximately 10% of all triploid gestations) (discussed later).


As will be discussed further in this chapter and as detailed in Table 30.7 , the diagnosis, classification, and differential diagnosis of GTD have undergone a major renaissance since the 1980s because of the genetic information obtained from these abnormal conceptuses combined with new biomarkers used for their diagnosis.



Table 30.7

Schematic of Changes in Classification of Trophoblastic Neoplasia, Including the Use of Biomarkers





























Decade Molar Categories Parameters Differential Diagnosis
1970s Hydatidiform mole grade 1-6 Morphology Hydropic abortus
1980s Partial and complete mole Genetics Hydropic abortus
1990s Partial and complete mole


  • Genetics



  • Morphology




  • Hydropic abortus



  • Trisomy 18



  • Mesenchymal dysplasia



  • Angiomatous malformation



  • Early complete mole



  • Diandric partial mole



  • Digynic triploidy



  • Twin mole–normal gestation

2000s Partial and complete mole p57 expression Complete mole versus other biology genetics


Target Cells and Tissues


Trophoblast differentiation has been described in detail earlier (see Chapter 29 ). Both villous and extravillous trophoblasts are subject to neoplastic transformation; specifically, it is thought that the proliferative phenotypes (villous cytotrophoblast, early implantation/cell column, and transitional extravillous trophoblast) are the cells of origin of trophoblast neoplasia ( Fig. 30.2 ). The non-proliferative, mature trophoblasts (the villous syncytiotrophoblast and mature extravillous trophoblast) are perceived as terminally differentiated and presumably not susceptible to neoplastic transformation, although their phenotypes are seen in the maturation of the other trophoblast neoplasia. It should be pointed out, however, that ultimately, all of these phenotypes are derived from the villous cytotrophoblast, the presumed trophoblastic stem/progenitor cell.




Fig. 30.2


Schematic of trophoblast differentiation and the cells of origin for various gestational trophoblastic diseases (GTDs).


The villous cytotrophoblast is considered the cell of origin for both CHM and choriocarcinoma. The diagnosis of both is predicated on the identification of both cytotrophoblastic proliferation and atypia. Cytotrophoblasts are considered trophoblast stem/progenitor cells, staining strongly for both p63 and proliferative markers, as well as cytokeratins, but essentially nonreactive for hCG, inhibin, and human placental lactogen (hPL) (see Chapter 29 ).


Syncytiotrophoblast , typically multinucleated, form abruptly in the chorionic villi from cytotrophoblasts and exhibit considerable cytoplasmic differentiation and stain intensely for human chorionic gonadotropin (hCG) and inhibin, albeit only in the first trimester (see Chapter 29 ). The syncytiotrophoblast cytoplasm can become vacuolated; these vacuoles can coalesce to form “lacunae,” in which case the cell assumes an irregular, lacy appearance. Such appearance of the syncytiotrophoblast can be seen in both complete and partial moles. In the complete mole, this component is distinctly immature, producing a lushly festooned arrangement of concentric syncytiotrophoblast that appears to cascade from the involved villi. In contrast, in the partial mole, the syncytiotrophoblastic “atypia” is more subdued, limited to smaller aggregates but still concentrically arranged in some villi. The term syncytiotrophoblastic hyperplasia is often applied to the villi in this context; however, the appearance is more likely the result of an abnormal trophoblastic maturation process rather than a proliferation of these cells.


The extravillous trophoblast is considered the cell of origin for both PSTT and epithelioid trophoblastic tumor (ETT) lesions, which are significantly less common than tumors of the villous trophoblast. Extravillous trophoblasts are derived from cytotrophoblast in two scenarios.


In early gestation, extravillous trophoblasts evolve beneath the cytotrophoblastic columns of anchoring early in gestation and invade the decidua and superficial myometrium. These cells are strongly immunoreactive for inhibin and MelCAM (also known as MCAM, MUC18, and CD146), as are the cells in their malignant counterpart, the PSTT. In their benign form, they are encountered in the endomyometrial implantation site early in pregnancy in association with Nitabuch fibrin.


Later in gestation, extravillous trophoblast emerge from the villi as they encounter extracellular matrix, whether it is fibrinoid following degeneration of chorionic villi in fetal membranes, at the basal plate, or in perivillous fibrin, such as in the intraplacental trophoblast islands throughout the placental disc (see Chapter 29 ). These cells have a variable phenotype, depending on where they are in transition from cytotrophoblast. The least mature, or “transitional” (epithelioid) extravillous trophoblasts have a more vacuolated cytoplasm, retain p63 and cyclin E expression, and their transformed counterpart defines the ETT. The more mature extravillous trophoblasts have a more eosinophilic cytoplasm and have fully lost their expression of p63. These cells are quite similar in immunophenotype to those seen in early implantation site or PSTTs, being inhibin and MelCAM positive. Unlike the PSTT, where immunophenotypically similar extravillous trophoblast are capable of rarely undergoing neoplastic transformation, in mature placenta and in ETTs these more mature extravillous trophoblast are a product of maturing transitional (epithelioid) trophoblast. Predictably, the mature extravillous trophoblast will be more conspicuous in normal gestational tissues or in residual placental site nodules following pregnancy and less likely to be encountered in ETTs where the tumor is composed primarily of non-maturing malignant transitional (epithelioid) trophoblast. This explains the low percentage of cells staining for MelCAM in ETTs. Both PSTT and ETT are strongly immunoreactive for cytokeratins, hPL, and GATA3, and weakly reactive for hCG, with ETTs being more variable in this regard. The most distinctive marker of ETT is p63 (see later), again because the transitional (epithelioid) trophoblast retains p63 expression.


These pathways of trophoblastic differentiation and their neoplastic counterparts are integrated schematically in Fig. 30.2 . One important point to address here is the difference in terminology, used in reference to extravillous trophoblast lineage in particular. In much of the literature, these cells have been referred to as “intermediate” trophoblast, mostly because, morphologically, they have a phenotype “intermediate” between cyto- and syncytiotrophoblast. However, because we have come to recognize that these cells represent the product of differentiation pathways distinct from that which takes place in chorionic villi (differentiation of cytotrophoblast into syncytiotrophoblast), we strongly believe that the more appropriate, and perhaps intuitive, term for these “nonvillous” trophoblast is “extravillous” trophoblast. In addition, elsewhere in the literature, the extravillous trophoblast has often been distinguished based on location in the placenta, and the origin of ETT is often attributed to “chorionic” trophoblast, the extravillous trophoblast in fetal membranes. Although the extravillous trophoblasts in the fetal membranes are indeed often vacuolated and correspond to the chorionic or epithelioid type, we interpret them as a differentiation pattern that is more generic, signifying a “transition” from cytotrophoblast to mature extravillous trophoblast that can be encountered in intraplacental fibrin and maternal surface, as well as the extraplacental membranes (see Chapter 29 ). Therefore, in attributing the origin of ETT to such “transitional” extravillous trophoblast, we expect that the origin could be either membranes or maternal surface of the placenta, the latter a very logical source for many retained implantation site nodules often encountered after pregnancy—and a presumed source of occasional ETTs—in the corpus (see Fig. 30.2 ).


Recent studies imply these trophoblast subtypes can be distinguished in part by their expression of one particular transcription factor, p63. p63 is related to both p53 and p73 and encodes two different isoforms, a full-length form resembling p53 (TAp63) and a truncated isoform (ΔNp63) that is commonly expressed in squamous epithelium. Trophoblastic columns, adjacent to villous structures in the early placenta, and villous cytotrophoblast strongly express ΔNp63. Cells in transition from the cytotrophoblast to mature extravillous trophoblast (“transitional” or epithelioid extravillous trophoblast) also express ΔNp63 (see Chapter 29 ), but syncytiotrophoblasts and the more mature extravillous trophoblasts are p63 negative. TAp63, on the other hand, is known to be expressed in extravillous trophoblast in the fetal membranes, but its expression in similar cells in intraplacental islands and the basal plate is less clear. The expression pattern of p63 suggests that, like in other epithelia, it is governed by both maturation and proximity of the trophoblast to supporting mesenchyme.


Despite biological differences between various cell types of the trophoblastic spectrum, all trophoblast phenotypes share common expression of some proteins. Definition of such overlapping gene expression patterns may be exploited in routine diagnostic practice in general and in particular for classifying tumors of the female reproductive tract having prominent atypia. Previously, the most useful markers common to all trophoblastic cell lineages were keratins, but its low sensitivity (as it also is expressed by carcinomas relevant to the typical differential diagnosis) hinders its usefulness. More recently, the enhancer-binding protein GATA3 has been found to be expressed in the majority (80% or better) of all trophoblast proliferations, both benign and malignant. Thus, detection of nuclear GATA3 expression in a difficult-to-classify tumor may be very helpful in recognizing its trophoblastic origin and excluding competing diagnoses of various high-grade müllerian carcinomas and pelvic tumors of unknown origin. Of course, one must be mindful that carcinomas arising from outside the müllerian system (i.e., urothelial and breast) also express GATA3. GATA3 expression also may decline in the chorionic villi of term placentas, but this does not pose any problems for diagnostic use. Thus, inclusion of GATA3 in tumor immunophenotyping panels may be helpful when evaluating difficult tumors in the proper clinical and pathologic context.


International Federation of Gynecology and Obstetrics Staging of Gestational Trophoblastic Disease


The modified International Federation of Gynecology and Obstetrics (FIGO) staging system for GTD is based on anatomic location ( Table 30.8 ), whereas the World Health Organization (WHO) score is based on a variety of prognostic factors ( Table 30.9 ). A combination of these two systems is applied to separate patients into “low-risk” (FIGO stage I to III with a WHO score of 6 or less) and “high-risk” (FIGO stage I to III with a WHO score of 7 or more, or FIGO stage IV) categories. Generally speaking, management of the low-risk patient is with single agent chemotherapy (methotrexate), whereas high-risk patients are treated with combination chemotherapy.


Feb 26, 2019 | Posted by in GYNECOLOGY | Comments Off on Trophoblast Neoplasia
Premium Wordpress Themes by UFO Themes